View Exam | PowerPak

1. In a hereditary transthyretin amyloidosis (hATTR) affected individual, the risk of transferring the disease to their offspring is:

A. 10% B. 25% C. 50% D. 100%

2. Which of the following patient presentations is consistent with hereditary transthyretin amyloidosis (hATTR)?

A. Heart failure and alternating episodes of diarrhea and constipation B. Skin lesions and elevated liver enzymes C. Pleural effusion and arthralgia D. Liver failure and parkinsonism

3. A patient is diagnosed with hereditary transthyretin amyloidosis (hATTR) and is displaying symptoms such as reduced ejection fraction, arrythmia, and syncope. Which therapy is the most appropriate to initiate in the patient?

A. Tafamidis B. Patisiran C. Inotersen D. Doxycycline and ursodeoxycholic acid

4. The most effective nonpharmacologic management strategy for hATTR is:

A. Liver transplant B. Hemodialysis C. Heart transplant D. Pacemaker implant

5. Pharmacologic medications decrease amyloid deposits through all mechanisms below, EXCEPT:

A. Inhibiting transthyretin (TTR) protein production B. Degrading TTR messenger RNA (mRNA) C. Stabilizing the TTR tetramer D. Metabolizing amyloid plaque deposits

6. Inotersen would be an appropriate therapeutic choice for each of the patients below, EXCEPT one:

A. With a history of New York Heart Association Class II heart failure B. With a history of squamous cell carcinoma C. Currently receiving dialysis D. With hypertension

7. Which of the following regarding patisiran administration is correct?

A. Premedications such as acetaminophen, corticosteroids, and histamine blockers are recommended B. The medication is administered via subcutaneous injection C. Infusion bags containing di(2-ethylhexyl)phthalate (DEHP) may be used for patisiran storage D. The drug may be infused at a rate of 10 mL/min

8. The acceptable standard practice for staging hATTR-associated disease is:

A. Clinical Staging of Transthyretin-Related Familial Amyloid Polyneuropathy (TTR-FAP) B. Polyneuropathy Disability Score (PND) C. Portuguese Classification D. None of the above

9. Which patient below presenting to the pharmacy may warrant a referral to a physician for hATTR evaluation? A patient…

A. Purchasing saline eye drops due to an increased number of dark “floaters” in the eye B. Needing a recommendation for toothpaste due to increased tooth sensitivity C. Complaining of consistent rhinorrhea for the past 7 days D. Purchasing hydrocortisone for a small maculopapular rash on their arm

10. Which of these steps regarding the inotersen Risk Evaluation Mitigation Strategy Program is INCORRECT?

A. The prescriber must be registered with the inotersen manufacturer before they may prescribe the drug B. A designated representative must be selected in the pharmacy where inotersen is distributed C. The patient must be enrolled in the inotersen monitoring program D. A maximum of 90 days of inotersen must be dispensed to the patient at one time

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. In a hereditary transthyretin amyloidosis (hATTR) affected individual, the risk of transferring the disease to their offspring is:

2. Which of the following patient presentations is consistent with hereditary transthyretin amyloidosis (hATTR)?

3. A patient is diagnosed with hereditary transthyretin amyloidosis (hATTR) and is displaying symptoms such as reduced ejection fraction, arrythmia, and syncope. Which therapy is the most appropriate to initiate in the patient?

4. The most effective nonpharmacologic management strategy for hATTR is:

5. Pharmacologic medications decrease amyloid deposits through all mechanisms below, EXCEPT:

6. Inotersen would be an appropriate therapeutic choice for each of the patients below, EXCEPT one:

7. Which of the following regarding patisiran administration is correct?

8. The acceptable standard practice for staging hATTR-associated disease is:

9. Which patient below presenting to the pharmacy may warrant a referral to a physician for hATTR evaluation? A patient…

10. Which of these steps regarding the inotersen Risk Evaluation Mitigation Strategy Program is INCORRECT?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. In a hereditary transthyretin amyloidosis (hATTR) affected individual, the risk of transferring the disease to their offspring is:

2. Which of the following patient presentations is consistent with hereditary transthyretin amyloidosis (hATTR)?

3. A patient is diagnosed with hereditary transthyretin amyloidosis (hATTR) and is displaying symptoms such as reduced ejection fraction, arrythmia, and syncope. Which therapy is the most appropriate to initiate in the patient?

4. The most effective nonpharmacologic management strategy for hATTR is:

5. Pharmacologic medications decrease amyloid deposits through all mechanisms below, EXCEPT:

6. Inotersen would be an appropriate therapeutic choice for each of the patients below, EXCEPT one:

7. Which of the following regarding patisiran administration is correct?

8. The acceptable standard practice for staging hATTR-associated disease is:

9. Which patient below presenting to the pharmacy may warrant a referral to a physician for hATTR evaluation? A patient…

10. Which of these steps regarding the inotersen Risk Evaluation Mitigation Strategy Program is INCORRECT?

« Return to Activity

Customers who Purchased
this Activity also Purchased